Log in
NASDAQ:PTI

Proteostasis Therapeutics Stock Forecast, Price & News

$1.12
+0.08 (+7.69 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.02
Now: $1.12
$1.13
50-Day Range
$1.04
MA: $1.31
$1.49
52-Week Range
$0.70
Now: $1.12
$4.72
Volume405,708 shs
Average Volume1.19 million shs
Market Capitalization$58.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.06
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.
Read More
Proteostasis Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.23 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTI
CUSIPN/A
Phone617-225-0096

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5 million
Book Value$1.22 per share

Profitability

Net Income$-59,130,000.00

Miscellaneous

Employees44
Market Cap$58.44 million
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$1.12
+0.08 (+7.69 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PTI News and Ratings via Email

Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions

How has Proteostasis Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Proteostasis Therapeutics' stock was trading at $1.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PTI stock has decreased by 3.4% and is now trading at $1.12.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Proteostasis Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Proteostasis Therapeutics
.

When is Proteostasis Therapeutics' next earnings date?

Proteostasis Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Proteostasis Therapeutics
.

How were Proteostasis Therapeutics' earnings last quarter?

Proteostasis Therapeutics Inc (NASDAQ:PTI) released its earnings results on Thursday, August, 6th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.04.
View Proteostasis Therapeutics' earnings history
.

What price target have analysts set for PTI?

5 brokerages have issued 12-month price objectives for Proteostasis Therapeutics' stock. Their forecasts range from $3.00 to $8.00. On average, they anticipate Proteostasis Therapeutics' stock price to reach $5.20 in the next twelve months. This suggests a possible upside of 364.3% from the stock's current price.
View analysts' price targets for Proteostasis Therapeutics
.

Are investors shorting Proteostasis Therapeutics?

Proteostasis Therapeutics saw a drop in short interest in September. As of September 15th, there was short interest totaling 2,000,000 shares, a drop of 13.0% from the August 31st total of 2,300,000 shares. Based on an average trading volume of 952,000 shares, the days-to-cover ratio is currently 2.1 days. Approximately 4.6% of the shares of the company are short sold.
View Proteostasis Therapeutics' Short Interest
.

Who are some of Proteostasis Therapeutics' key competitors?

What other stocks do shareholders of Proteostasis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include Idera Pharmaceuticals (IDRA), BHP Group (BHP), Sorrento Therapeutics (SRNE), Amarin (AMRN), Matinas BioPharma (MTNB), Opko Health (OPK), Micron Technology (MU), Paratek Pharmaceuticals (PRTK), Rite Aid (RAD) and VBI Vaccines (VBIV).

Who are Proteostasis Therapeutics' key executives?

Proteostasis Therapeutics' management team includes the following people:
  • Ms. Meenu Chhabra, Pres, CEO, Interim Principal Financial & Accounting Officer and Director (Age 48, Pay $844.78k)
  • Ms. Sheila Gilbride Wilson M.B.A., Chief Operating Officer (Age 62, Pay $521.96k)
  • Dr. Po-Shun Lee, Consultant (Age 51, Pay $545.85k)
  • Dr. Marija Zecevic, Chief Commercial Officer (Age 46, Pay $530.46k)
  • Dr. Benito Munoz, Chief Scientific Officer (Age 58)

When did Proteostasis Therapeutics IPO?

(PTI) raised $51 million in an IPO on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

What is Proteostasis Therapeutics' stock symbol?

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

Who are Proteostasis Therapeutics' major shareholders?

Proteostasis Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include WINTON GROUP Ltd (1.58%), Bridgeway Capital Management Inc. (0.61%), Two Sigma Advisers LP (0.36%), Goldman Sachs Group Inc. (0.07%), Virtu Financial LLC (0.07%) and Blair William & Co. IL (0.06%). Company insiders that own Proteostasis Therapeutics stock include Enterprise Associates 12 New, Franklin M Berger, Meenu Chhabra and Po Shun Lee.
View institutional ownership trends for Proteostasis Therapeutics
.

Which institutional investors are buying Proteostasis Therapeutics stock?

PTI stock was bought by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., WINTON GROUP Ltd, Goldman Sachs Group Inc., Virtu Financial LLC, Commonwealth Equity Services LLC, Two Sigma Advisers LP, and Blair William & Co. IL.
View insider buying and selling activity for Proteostasis Therapeutics
.

How do I buy shares of Proteostasis Therapeutics?

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Proteostasis Therapeutics' stock price today?

One share of PTI stock can currently be purchased for approximately $1.12.

How big of a company is Proteostasis Therapeutics?

Proteostasis Therapeutics has a market capitalization of $58.44 million and generates $5 million in revenue each year. The company earns $-59,130,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Proteostasis Therapeutics employs 44 workers across the globe.

What is Proteostasis Therapeutics' official website?

The official website for Proteostasis Therapeutics is www.proteostasis.com.

How can I contact Proteostasis Therapeutics?

Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.